The global immune thrombocytopenia market size reached a value of more than USD 3.04 billion in 2021, driven by increasing investments by various governments, rising awareness about the condition, and growing number of patients.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Immune thrombocytopenia or ITP is a platelet disorder in which the platelet count within blood is low, due to which blood does not clot adequately, resulting in extensive bleeding and bruising in the case of any injury. It may be caused by the immune system mistakenly attacking and destroying the platelets. Although there is no cure available for immune thrombocytopenia, changing the lifestyle and diet can provide relief.
Immune thrombocytopenia is a prevalent disorder found among people all around the globe. Increased awareness and diagnostic capabilities are leading to an increased number of patients diagnosed with the condition, contributing to the growth of the immune thrombocytopenia market significantly.
Regulatory bodies such as the United States’ Food and Drug Administration are approving various treatments and medicines at a speedy pace to improve the health of the people at a faster rate which is also fuelling the market growth.
Key players are carrying out research and developing new methods of treatment, aiming towards improvement of the condition and a long-term cure. As the number of people diagnosed with immune thrombocytopenia increase, there is greater demand for effective treatments and cures.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on type, the market can be bifurcated into acute and chronic. On the basis of treatment, the market is segmented into thrombopoietin receptor agonist, immunoglobulins, and corticosteroids, among others. Based on end use, the market is categorised into hospitals and clinics, research organisation, and other users. By region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global immune thrombocytopenia market covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.
Acute immune thrombocytopenia is most common and prevalent form of the condition which has made it the leader in the market for immune thrombocytopenia. It usually lasts less than 6 months and often occurs in children. Chronic immune thrombocytopenia typically occurs in adults and has a long-term impact. In chronic immune thrombocytopenia, platelets are destroyed or suppressed because of immune system’s reaction with platelet autoantigens.
North America is expected to dominate the immune thrombocytopenia market because of the prevalence of the condition in the region. Also, the continuous strides by the key players to develop new technologies is contributing to the growth of the market in North America. In the Asia Pacific region, increasing in population and growing expenditure on healthcare and healthcare infrastructure are anticipated to fuel the market growth in the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rigel Pharmaceuticals Inc. is an American biotechnology company that was established in 1996 with headquarters in California, United States. They work with an aim to provide a better life to people suffering from immune diseases and cancer patients by developing small molecule drugs.
Amgen Inc. founded in 1980 is headquartered in California, United States. This biopharmaceutical company researches, innovates, develops, and supplies medicines to treat patients affected by serious diseases.
Novartis AG was founded in 1996 and is based out of Basel, Switzerland. It is a Swiss-American pharmaceutical company that is known for developing medicines with an aim to make every person healthy in order to extend their lives.
Other market players include CSL Limited, and Octapharma AG, among others.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Treatment Type||
|Breakup by Diseases Type||
|Breakup by Route of Administration||
|Breakup by End User||
|Breakup by Treatment Channel||
|Breakup by Distribution Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Immune Thrombocytopenia Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Immune Thrombocytopenia Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Immune Thrombocytopenia Epidemiology (2016-2031)
5.3 Europe Immune Thrombocytopenia Epidemiology (2016-2031)
5.4 Asia-Pacific Immune Thrombocytopenia Epidemiology (2016-2031)
5.5 Latin America Immune Thrombocytopenia Epidemiology (2016-2031)
5.6 Middle East & Africa Immune Thrombocytopenia Epidemiology (2016-2031)
6 Global Immune Thrombocytopenia Market Overview
6.1 Global Immune Thrombocytopenia Market Historical Value (2016-2022)
6.2 Global Immune Thrombocytopenia Market Forecast Value (2023-2031)
7 Global Immune Thrombocytopenia Market Landscape
7.1 Global Immune Thrombocytopenia: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Immune Thrombocytopenia Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by End User
8 Immune Thrombocytopenia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Immune Thrombocytopenia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Immune Thrombocytopenia Market Segmentation
11.1 Global Immune Thrombocytopenia Market by Treatment Type
11.1.1 Market Overview
220.127.116.11 Thrombopoietin Receptor Agonists
18.104.22.168 Intravenous Immunoglobulins
11.2 Global Immune Thrombocytopenia Market by Diseases Type
11.2.1 Market Overview
11.3 Global Immune Thrombocytopenia Market by Route of Administration
11.3.1 Market Overview
11.4 Global Immune Thrombocytopenia Market by End User
11.4.1 Market Overview
11.4.4 Specialty Centres
11.5 Global Immune Thrombocytopenia Market by Treatment Channel
11.5.1 Market Overview
11.6 Global Immune Thrombocytopenia Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Online Pharmacy
11.6.4 Retail Pharmacy
11.7 Global Immune Thrombocytopenia Market by Region
11.7.1 Market Overview
11.7.2 North America
11.7.4 Asia Pacific
11.7.5 Latin America
11.7.6 Middle East and Africa
12 North America Immune Thrombocytopenia Market
12.1 Market Share by Country
12.2 United States of America
13 Europe Immune Thrombocytopenia Market
13.1 Market Share by Country
13.2 United Kingdom
14 Asia Pacific Immune Thrombocytopenia Market
14.1 Market Share by Country
15 Latin America Immune Thrombocytopenia Market
15.1 Market Share by Country
16 Middle East and Africa Immune Thrombocytopenia Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.5 South Africa
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Pfizer Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.2 F. Hoffmann-La Roche Ltd.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.3 Mylan N.V.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.4 Fresenius Kabi AG
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.5 Hikma Pharmaceuticals PLC
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.6 Hepalink Group.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.7 Teva Pharmaceutical Industries Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.8 Amarillo Biosciences, Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.9 Bolder Bio Technology, Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.10 GENOSCO Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.11 Hansa Biopharma
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.12 Janssen Pharmaceuticals, Inc.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.13 Eisai Co., Ltd (Japan)
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
24 Immune Thrombocytopenia Market- Distribution Model (Additional Insight)
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The global market size for immune thrombocytopenia reached a value of more than USD 3.04 billion in 2021.
Key market drivers are increasing investments by various governments, rising awareness about the condition, and growing number of patients.
The key trends of the market are easy diagnostics, approval by regulatory bodies, and research and development activities carried out by the key players.
Key market players include Rigel Pharmaceuticals, Inc., Amgen Inc., Novartis AG, CSL Limited, and Octapharma AG, among others.
Immune thrombocytopenia is a platelet disorder in which the platelet count within blood is low, due to which blood does not clot adequately, resulting in extensive bleeding and bruising in the case of any injury.
Immune thrombocytopenia can be caused by the immune system mistakenly attacking and destroying platelets which would otherwise help in blood clotting.
Immune thrombocytopenia leads to improper or insufficient blood clotting due to presence of low platelets, resulting in excessive bleeding or bruising.
The global immune thrombocytopenia market is segmented based on type, treatment, end use, and region.
On the basis of treatment, the market is segmented into thrombopoietin receptor agonist, immunoglobulins, corticosteroids among other treatments.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.